eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2013
vol. 51
 
Share:
Share:
more
 
 
abstract:
Original paper

Effectiveness and safety of the use of rituximab in patients with active rheumatoid rthritis – 5 years’ personal observations

Jolanta Parada-Turska
,
Paweł Dudek
,
Renata Seweryn
,
Maria Majdan

Reumatologia 2013; 51, 1: 20-25
Online publish date: 2013/03/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The aim of this study was to assess the effectiveness and safety of rituximab (RTX) treatment in patients with severe, active rheumatoid arthritis (RA) in the years 2007–2012.

Material and methods: The study was conducted on 38 adult patients with active RA (DAS28 > 3.2) who were enrolled in the RTX treatment program as a second or third line drug. The primary or secondary ineffectiveness of anti-TNF therapy was observed in those patients. The group consisted of 31 women (81.6%) and 7 men (18.4%). The average age was 54.6 ±11.25 years, and the average duration of RA was 16.3 ±7.9 years. The RTX effectiveness was assessed during 36 months using EULAR criteria.

Results: At the 6th, 12th, 24th, 30th and 36th month of observation a good response to RTX treatment was demonstrated by 18.4%, 30.0%, 21.7%, 64.3% and 88.9% of patients, respectively. At the same time a moderate response was found in 73.7%, 53.3%, 60.9%, 14.3% and 0.0% and no response in 7.9%, 16.7%, 17.4%, 21.4% and 11.1% of patients, respectively. There were 2 non-responders (5.3%) to the initial treatment with RTX. We observed secondary ineffectiveness of RTX therapy in 10 patients (26.3%).

During the course of RTX treatment the number of patients receiving oral corticosteroids was reduced from 34 (89.5%) to 16 (42.1%) (p < 0.001). In the remaining patients the mean dose of corticosteroids was lowered by 23.8%. The following adverse effects during RTX infusion were recorded in 3 (7.9%) patients: Quincke’s edema, hypotonia and itching of the skin. Infections were observed in 5 (13.1%) of the treated patients.

Conclusions: RTX treatment is a safe and effective form of therapy in patients with active, long-term RA previously treated with various DMARDs.
keywords:

rheumatoid arthritis, rituximab, biological therapy




Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe